NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON
Peptide testing

Ordered peptides from ZZQ Peptides? Mail in a sample (US only) and let us test it.

Test my supply
+1 more ↓
67%
Finnrick rating
#347 of 498 ranked vendors
35 of 51 classifiable tests passed
methodology · Purity focus
Finnrick analysis

ZZQ Peptides shows its strongest purity-focus evidence in GHK-Cu and Retatrutide, where later results are mostly passing despite earlier fill, identity, and batch-ID outliers. Tirzepatide is more volatile, and Tesamorelin is the weakest line with repeated purity misses; the record is current and fairly broad, but documentation and failures remain uneven.

methodology →
vendor intelligence report
Vendor Intelligence Report: ZZQ Peptides

Beyond the lab numbers, ZZQ’s current WhatsApp contact resolves to a Quenna-branded business profile while a sister storefront uses the same email-domain layer. The report maps the Haigui provider trail, parked Quenna storefront, and batch-control gaps.

35 pages8 risk factors assessed11 Nov 2026
read the report
Peptides
#
Peptide
$/MG
Rating
N
1
GHK-Cu
$0.06
85%
6
2
Retatrutide
$0.67
81%
18
3
Tirzepatide
$0.55
64%
20
6
BPC-157
$0.85
-
0
7
Semaglutide
$0.60
-
0
9
TB-500
-
-
0
Contact channels
Rating trend
CUMULATIVE FINNRICK RATING
83%+65%+48%+30%+<30%17 Dec 2025: 68%17 Dec 2025: 68%17 Dec 2025: 68%18 Dec 2025: 65%29 Dec 2025: 66%1 Jan 2026: 66%6 Jan 2026: 65%9 Jan 2026: 65%29 Jan 2026: 65%2 Feb 2026: 67%18 Feb 2026: 67%18 Feb 2026: 67%18 Feb 2026: 66%18 Feb 2026: 66%18 Feb 2026: 66%20 Feb 2026: 67%20 Feb 2026: 67%20 Feb 2026: 67%4 Mar 2026: 66%4 Mar 2026: 65%4 Mar 2026: 64%4 Mar 2026: 64%10 Mar 2026: 64%10 Mar 2026: 63%18 Mar 2026: 63%21 Mar 2026: 64%25 Mar 2026: 64%28 Apr 2026: 64%28 Apr 2026: 64%28 Apr 2026: 64%28 Apr 2026: 64%6 May 2026: 65%8 May 2026: 65%18 May 2026: 65%18 May 2026: 66%24 Jun 2026: 66%26 Jun 2026: 66%4 Aug 2026: 66%27 Aug 2026: 66%6 Oct 2026: 66%12 Nov 2026: current 67%68%64%67%Dec 25Nov 26
Peptide testing

Ordered peptides from ZZQ Peptides? Mail in a sample (US only) and let us test it.

Test my supply
ZZQ Peptides test history
COA-backed lab tests
DateResultTestLabPurityDosageLabelCOA
6 Oct 2026
Pass
Retatrutide
lab nameView COA
27 Aug 2026
Fail
Tirzepatide
lab nameView COA
4 Aug 2026
Pass
Retatrutide
lab nameView COA
26 Jun 2026
Pass
Tirzepatide
lab nameView COA
24 Jun 2026
Pass
Retatrutide
lab nameView COA
24 May 2026
Incomplete
Tirzepatide
lab nameView COA
18 May 2026
Pass
Tirzepatide
lab nameView COA
18 May 2026
Pass
Tirzepatide
lab nameView COA
8 May 2026
Pass
Retatrutide
lab nameView COA
6 May 2026
Pass
Tirzepatide
lab nameView COA
1-10 of 52

About ZZQ Peptides test results from Finnrick

ZZQ Peptides is a peptide vendor tracked in Finnrick's independent testing dataset. This page compiles batch-level results across 5 peptides and 52 tests, including ratings, observed price signals, recent test dates, and correction history where available.

Finnrick ratings are calculated from published sample data using the selected rating standard. The default standard evaluates purity, dose accuracy, and label quality, then adjusts low-volume results so small sample counts do not appear more certain than the data supports.

The most visible ZZQ Peptides peptides in this dataset are Cagrilintide (3 tests), GHK-Cu (6 tests) and Retatrutide (18 tests). Use the peptide table above to compare the current Finnrick rating, price per mg, and sample volume for each peptide.

Recent tests and corrections are shown below when available. Samples may be acquired by Finnrick directly or submitted through Finnrick testing programs; the goal is to make safety and supply-chain evidence easier to evaluate than vendor marketing claims alone. This page currently lists 52 recent tests.

Corrections
No corrections.
Peptide testing

Ordered peptides from ZZQ Peptides? Mail in a sample (US only) and let us test it.

Test my supply